Volume 31, Issue 144 (January & February 2023)                   J Adv Med Biomed Res 2023, 31(144): 64-72 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghorbani M, Mahmoudian A, Abtahi Froushani S M, Ownagh A, Tokmahchi A. Lactobacillus Acidophilus Regulates the Expression of MicroRNAs and Ameliorates the Symptoms of Acid-induced Ulcerative Colitis in Rats. J Adv Med Biomed Res 2023; 31 (144) :64-72
URL: http://journal.zums.ac.ir/article-1-6858-en.html
Lactobacillus Acidophilus Regulates the Expression of MicroRNAs and Ameliorates the Symptoms of Acid-induced Ulcerative Colitis in Rats
Mahvash Ghorbani1 , Alireza Mahmoudian * 2, Seyyed Meysam Abtahi Froushani1 , Abdolghaffar Ownagh1 , Amir Tokmahchi1
1- Dept. of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran
2- Dept. of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran , alireza_mah@yahoo.com
Abstract:   (10734 Views)

Background and Objective: Ulcerative colitis (UC) is an unknown recurrent intestinal disease and a common cause of gastrointestinal disorders, which may lead to colorectal cancer if not diagnosed and treated in a timely manner. The beneficial effects of several probiotics in diseases like inflammatory bowel disease (IBD) have been investigated, although their mechanisms have not been yet fully understood. In this study, we investigated the possible association between the changes in the levels of the expression of miRNAs and the anti-inflammatory activity of the L. acidophilus as a probiotic model in Wistar rats suffering the acid-induced UC.
Materials and Methods: Twenty rats were randomly divided into four groups. To induce colitis, the rats were briefly anesthetized, and 1 ml of acetic acid (4%) was injected into their rectum using a Foley catheter, as explained previously.  L. acidophilus was given orally (3×108 CCU/ml) for 10 days. The rats were monitored daily for clinical signs for 10 days. Following euthanasia, the macroscopic and microscopic pathological lesions in the intestinal tissues were examined. Additionally, the total RNA from specimens were extracted, and the expression levels of mRNAs for cytokines, including TNFα, IL-1β, IL-6, IL-10, IFN-γ, and the expression levels of miR-1, miR-155, miR-let7d, and miR-99a were determined using the qPCR method.
Results: The clinical signs and pathological damages induced by acid were ameliorated in the rats receiving L. acidophilus compared with rats that did not receive it, as evidenced by improved clinical signs and results of immunohistochemistry and chemical assays. miRNAs, including miR-1, miR-99, miR-Let7d and miR-155 and changes in the expression of mRNAs, including TNFα, IL-1β, IL-6, IL-10 and IFN-γ were significant. Changes in the amount of myeloperoxidase, nitrite oxide, and malondialdehyde were also significant (P ≤ 0.05). In pathological examination, immune cell infiltration and COX2 were different in colitis and treatment groups.
Conclusion: Therapeutic use of probiotics ameliorated UC by significantly changing the levels of miR-1, miR-99, miR-Let7d and miR-155.

Keywords: Lactobacillus acidophilus, MicroRNA, Ulcerative colitis
Full-Text [PDF 906 kb]   (10062 Downloads) |   |   Full-Text (HTML)  (751 Views)  

✅ Therapeutic use of probiotics ameliorated UC by significantly changing the levels of miR-1, miR-99, miR-Let7d and miR-155.


Type of Study: Original Article | Subject: Life science
Received: 2022/01/18 | Accepted: 2022/07/13 | Published: 2022/12/12
References
1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet. 2007;369(9573):1641-57. [DOI:10.1016/S0140-6736(07)60751-X]
2. Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut microbiota and immune system interactions. Microorganisms. 2020;8(10):1587. [DOI:10.3390/microorganisms8101587] [PMID] [PMCID]
3. Aponte M, Murru N, Shoukat M. Therapeutic, prophylactic, and functional use of probiotics: a current perspective. Front Microbiol. 2020;11:2120. [DOI:10.3389/fmicb.2020.562048] [PMID] [PMCID]
4. Ailioaie LM, Litscher G. Probiotics, photobiomodulation, and disease management: Controversies and challenges. Int J Molec Sci. 2021;22(9):4942. [DOI:10.3390/ijms22094942] [PMID] [PMCID]
5. Llewellyn A, Foey A. Probiotic modulation of innate cell pathogen sensing and signaling events. Nutrients. 2017;9(10):1156. [DOI:10.3390/nu9101156] [PMID] [PMCID]
6. Abdulkhaleq L, Assi M, Abdullah R, Zamri-Saad M, Taufiq-Yap Y, Hezmee M. The crucial roles of inflammatory mediators in inflammation: A review. Veterinary World. 2018;11(5):627. [DOI:10.14202/vetworld.2018.627-635] [PMID] [PMCID]
7. Wang Z, Li S, Cao Y, et al. Oxidative stress and carbonyl lesions in ulcerative colitis and associated colorectal cancer. Oxid Med Cell Long. 2016;2016. [DOI:10.1155/2016/9875298] [PMID] [PMCID]
8. Kalla R, Ventham N, Kennedy N, et al. MicroRNAs: new players in IBD. Gut. 2015;64(3):504-13. [DOI:10.1136/gutjnl-2014-307891] [PMID] [PMCID]
9. Rodríguez-Nogales A, Algieri F, Garrido-Mesa J, et al. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition. J Nutr Biochem. 2018;61:129-39. [DOI:10.1016/j.jnutbio.2018.08.005] [PMID]
10. Valmiki S, Ahuja V, Paul J. MicroRNA exhibit altered expression in the inflamed colonic mucosa of ulcerative colitis patients. World J Gastroenterol. 2017;23(29):5324. [DOI:10.3748/wjg.v23.i29.5324] [PMID] [PMCID]
11. Luo X, Ranade K, Talker R, Jallal B, Shen N, Yao Y. MicroRNA-mediated regulation of innate immune response in rheumatic diseases. Arthritis Res Ther. 2013;15(2):1-13. [DOI:10.1186/ar4194] [PMID] [PMCID]
12. Rodríguez-Nogales A, Algieri F, Garrido-Mesa J, et al. The administration of Escherichia coli Nissle 1917 ameliorates development of DSS-induced colitis in mice. Front Pharmacol. 2018;9:468. [DOI:10.3389/fphar.2018.00468] [PMID] [PMCID]
13. Frăţilă O, Iliaş TI. COX-2 and Ki-67 immunohistochemical markers in the assessment of long-standing ulcerative colitis associated dysplasia. Rom J Morphol Embryol. 2013;54(1):143-9.
14. Mahmoudian A, Markham PF, Noormohammadi AH, Browning GF. Kinetics of transcription of infectious laryngotracheitis virus genes. Compar Immunol, Microbiol Infect Dis. 2012;35(2):103-15. [DOI:10.1016/j.cimid.2011.11.001] [PMID]
15. Abtahi Froushani SM, Mashouri S. The beneficial effects of hypiran in ameliorating rat model of ulcerative colitis. Zahedan J Res Med Sci. 2018;20(1). [DOI:10.5812/zjrms.58919]
16. Sun Y, Li L, Xie R, Wang B, Jiang K, Cao H. Stress triggers flare of inflammatory bowel disease in children and adults. Front Pediatr. 2019;7:432. [DOI:10.3389/fped.2019.00432] [PMID] [PMCID]
17. Hu T, Wang H, Xiang C, Mu J, Zhao X. Preventive effect of Lactobacillus acidophilus XY27 on DSS-induced ulcerative colitis in mice. Drug Design Develop Ther. 2020;14:5645. [DOI:10.2147/DDDT.S284422] [PMID] [PMCID]
18. Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene. 2010;29(15):2161-4. [DOI:10.1038/onc.2010.59] [PMID]
19. Jung H, Kim JS, Lee KH, et al. Roles of microRNAs in inflammatory bowel disease. Int J Biol Sci. 2021;17(8):2112-23. [DOI:10.7150/ijbs.59904] [PMID] [PMCID]
20. Li M, Marin-Muller C, Bharadwaj U, Chow KH, Yao Q, Chen C. MicroRNAs: control and loss of control in human physiology and disease. World J Surg. 2009;33(4):667-84. [DOI:10.1007/s00268-008-9836-x] [PMID] [PMCID]
21. Grondin JA, Kwon YH, Far PM, Haq S, Khan WI. Mucins in intestinal mucosal defense and inflammation: learning from clinical and experimental studies. Front Immunol. 2020;11:2054. [DOI:10.3389/fimmu.2020.02054] [PMID] [PMCID]
22. Chen W, Zhuo M, Lu X, et al. SRC-3 protects intestine from DSS-induced colitis by inhibiting inflammation and promoting goblet cell differentiation through enhancement of KLF4 expression. Int J Biol Sci. 2018;14(14):2051. [DOI:10.7150/ijbs.28576] [PMID] [PMCID]
23. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000. [DOI:10.1161/ATVBAHA.110.207449] [PMID] [PMCID]
24. Hou Y, Janczuk A, Wang P. Current trends in the development of nitric oxide donors. Curr Pharmaceut Des. 1999;5(6):417-42.
25. Krishn SR, Batra SK, Kaur S. Advances in miRNA-mediated mucin regulation. Curr Pharmacol Rep. 2015;1(6):355-64. [DOI:10.1007/s40495-014-0010-x] [PMID] [PMCID]
26. Ahrne S, Johansson Hagslatt M-L. Effect of lactobacilli on paracellular permeability in the gut. Nutrients. 2011;3(1):104-17. [DOI:10.3390/nu3010104] [PMID] [PMCID]
27. Cichon C, Sabharwal H, Rüter C, Schmidt MA. MicroRNAs regulate tight junction proteins and modulate epithelial/endothelial barrier functions. Tissue Barriers. 2014;2(4):e944446. [DOI:10.4161/21688362.2014.944446] [PMID] [PMCID]
28. Wan J, Xia L, Xu W, Lu N. Expression and function of miR-155 in diseases of the gastrointestinal tract. Int J Molec Sci. 2016;17(5):709. [DOI:10.3390/ijms17050709] [PMID] [PMCID]
29. Hübenthal M. Phenotype prediction based on microRNA expression profiles: a novel diagnostic tool for inflammatory bowel disease 2019. https://macau.uni-kiel.de/receive/diss_mods_00025631.
30. James JP, Riis LB, Malham M, Høgdall E, Langholz E, Nielsen BS. MicroRNA biomarkers in IBD-differential diagnosis and prediction of colitis associated cancer. Int J Molec Sci. 2020;21(21):7893. [DOI:10.3390/ijms21217893] [PMID] [PMCID]
31. Mueller AC, Sun D, Dutta A. The miR-99 family regulates the DNA damage response through its target SNF2H. Oncogene. 2013;32(9):1164-72. [DOI:10.1038/onc.2012.131] [PMID] [PMCID]
32. Okayama H, Schetter AJ, Harris CC. MicroRNAs and inflammation in the pathogenesis and progression of colon cancer. Digest Disease. 2012;30(Suppl. 2):9-15. [DOI:10.1159/000341882] [PMID] [PMCID]
33. Coskun M, Bjerrum JT, Seidelin JB, Troelsen JT, Olsen J, Nielsen OH. miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol. 2013;19(27):4289. [DOI:10.3748/wjg.v19.i27.4289] [PMID] [PMCID]
34. Han C, Yu Z, Duan Z, Kan Q. Role of microRNA-1 in human cancer and its therapeutic potentials. Biomed Res Int. 2014;2014. [DOI:10.1155/2014/428371] [PMID] [PMCID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb  Co-Publisher: Farname Inc.